DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 04/04/2019 --Epidermolysis Bullosa - Epidemiology and Market Forecast-2028

Epidermolysis Bullosa overall incidence and prevalence were at 19.6 and 11.07 cases per 1 million live births respectively.

1. Epidermolysis Bullosa overall prevalence during the first 5 years was at 8.22 per 1 million live births. When reassessed over the entire 16 years of the study, the prevalence rose to 11.07.
2. Only a modest 10.6% reduction was seen in those with Dystrophic Epidermolysis Bullosa in whom the genetic mode of transmission was unknown due to reclassification and addition of newer subtypes.

DelveInsight launched a new report on Epidermolysis Bullosa - Market Insights, Epidemiology and Market Forecast-2028

Request for sample pages

Key benefits

- Epidermolysis Bullosa report will help to develop Business Strategies by understanding the trends shaping and driving the Epidermolysis Bullosa market.
- Organize sales and marketing efforts by identifying the best opportunities for Epidermolysis Bullosa market.
- To understand the future market competition in the Epidermolysis Bullosa market.

"Epidermolysis Bullosa is broadly classified into four types: Epidermolysis Bullosa Simplex (EBS), Junctional Epidermolysis Bullosa (JEB), Dystrophic Epidermolysis Bullosa (DEB) and Kindler Syndrome."

Epidermolysis Bullosa types are characterized by fragile skin and a range of cutaneous involvement from blistering, primarily on the hands and feet, through to more generalized wounding, Skin and Wound Management is primarily required. The presence of multiple wounds of varying duration and ability to heal makes Epidermolysis Bullosa management difficult and complex.

Currently, there is no approved therapy available for the Epidermolysis Bullosa treatment. The management of the disease majorly comprises of supportive treatment options, involving the integration of multidisciplinary management of wound healing, pain, nutrition, physical disabilities that may require additional physical and occupational therapies as well as surgical interventions.

Epidermolysis Bullosa treatment involves managing skin-related symptoms (wound healing and infection control), Gastrointestinal events (the most disabling complication is esophageal lesions associated with Hallopeau-Siemens and inverse recessively inherited epidermolysis bullos subtypes), Pruritus (Pharmacologic interventions commonly utilized for pruritus in EB include sedating and non-sedating antihistamines, antidepressants, and the centrally acting compounds such as gabapentin and pregabalin), Eye lesions (Patients with Epidermolysis Bullosa Simplex (EBS), can experience recurrent blepharitis in one or both eyes along with bullous lesions of the conjunctivae), Oral care (maintaining good dental hygiene is essential) and Pain Management (For mild pain simple analgesics, such as paracetamol and ibuprofen are recommended while opioids and anxiolytics are necessary for severe pain associated with dressing changes). Epidermolysis Bullosa potential future therapies include: protein, cell, and gene therapies; which will contribute to the growth of Epidermolysis Bullosa market size during forecast period (2018 - 2028).

Companies that are involved are-
1. Castle
2. Creek Pharmaceuticals
3. Amryt Pharma
4. Abeona Therapeutics
5. RegeneRx Biopharmaceuticals Inc.
and many others.
Drugs that are involved are
1. CCP-020
2. AP101
3. RGN-137
And many others

Table of contents

1. Report Introduction
2. Epidermolysis Bullosa Market Share at a glance
3. Epidermolysis Bullosa Disease Background and Overview
4. Epidermolysis Bullosa Epidemiology and Patient Population
5. Epidermolysis Bullosa Country Wise Epidemiology
5.1. United States
5.2. EU5
5.2.1. Germany
5.2.2. Italy
5.2.3. Spain
5.2.4. France
5.2.5. United Kingdom
5.3. Japan
6. Epidermolysis Bullosa Treatment Algorithm
7. Epidermolysis Bullosa Current Unmet Needs
8. Epidermolysis Bullosa Therapeutics under Development by Companies
8.1. Key Cross Competition
8.2. Emerging Products
8.2.1. CCP-020: Castle Creek Pharmaceuticals
8.2.2. EB-101: Abeona Therapeutics
8.2.3. RGN-137: RegeneRx Biopharmaceuticals
8.2.4. PTR-01: Phoenix Tissue Repair, Inc.
9. Epidermolysis Bullosa Market Size
10. Epidermolysis Bullosa 7MM Market analysis
11. Epidermolysis Bullosa Region-Wise Market size
11.1. United States
11.2. EU-5
11.2.1. Spain
11.2.2. United Kingdom
11.2.3. Italy
11.2.4. Germany
11.2.5. France
11.3. Japan
12. Market Drivers
13. Market Barriers
14. Appendix
15. Report Methodology
16. DelveInsight Capabilities
17. Disclaimer

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight